Cargando…
Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials
Autores principales: | Nelson, M, Amaya, G, Clumeck, N, Arns Da Cunha, C, Jayaweera, D, Junod, P, Taisheng, L, Tebas, P, Stevens, M, Buelens, A, Vanveggel, S, Boven, K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112995/ http://dx.doi.org/10.1186/1758-2652-13-S4-P210 |
Ejemplares similares
-
Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE
por: Crauwels, HM, et al.
Publicado: (2010) -
Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients
por: Cohen, C, et al.
Publicado: (2010) -
A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants
por: Johnson, Barry C, et al.
Publicado: (2012) -
HBV and HCV Infection in Children and Adolescents
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2023) -
Outcomes in Older Versus Younger Patients Over 96 Weeks in HIV-1– Infected Patients Treated with Rilpivirine or Efavirenz in ECHO and THRIVE§
por: Ryan, Robert, et al.
Publicado: (2013)